Verastem on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma; shares ahead 3%

|By:, SA News Editor

Based on FDA feedback, Verastem's (VSTM +3.3%) New Drug Application (NDA) seeking approval for duvelisib will include requests for full approval for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and accelerated approval for relapsed/refractory follicular lymphoma (FL).

The company expects to submit the NDA in Q1 2018.

Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.

Previously: Verastem's duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket (Sept. 6)

Subscribe for full text news in your inbox